TRIPLE NEGATIVE BREAST CANCER (TNBC)
Clinical trials for TRIPLE NEGATIVE BREAST CANCER (TNBC) explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST CANCER (TNBC) trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New RNA vaccine aims to stop breast cancer return
Disease control Recruiting nowThis early-stage trial tests an investigational cancer vaccine called ITI-5000 in 60 people with stage II-III triple-negative breast cancer who have finished standard treatment. The vaccine uses self-amplifying RNA to teach the immune system to attack cancer cells. The study firs…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Immunomic Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug XB010 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug EXS74539 enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New precision approach aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo attack on aggressive breast cancer shows promise in early trial
Disease control Recruiting nowThis study tests whether using focused ultrasound (HIFU) to destroy tumors, with or without an immune-boosting drug (PD-1 inhibitor), before standard chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer. About 58 participants will receive on…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can adding radiation to immunotherapy and chemotherapy boost breast cancer treatment?
Disease control Recruiting nowThis phase 2 trial is testing whether adding low or high dose radiation to standard chemotherapy and the immunotherapy drug pembrolizumab can improve treatment for people with node-positive triple negative breast cancer. Thirty-two participants will be randomly assigned to receiv…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New blood test could spot hidden breast cancer before scans do
Disease control Recruiting nowThis study is for people with a high-risk type of breast cancer (triple-negative) who still have cancer cells left after standard treatment and surgery. Researchers will use a special blood test (ctDNA) to look for tiny traces of cancer DNA that scans might miss. If the test find…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a second ADC tame breast cancer after the first fails?
Disease control Recruiting nowThis study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibody drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, an…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Epsilogen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Gut bacteria boost? probiotic added to chemo in breast cancer trial
Disease control Recruiting nowThis study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery can help eliminate more cancer cells in women with early-stage triple-negative breast cancer. About 192 participants will receive either standard treatment alone or standard trea…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer, including HER2-positive and triple-negative types. About 60 adults whose cancer has not responded to standard treatments will receive cells tailored to their t…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for aggressive breast cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding the drug AK112 to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 416 adults who have not had prior treatment for advanced disease will be randomly assi…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo aims to wipe out aggressive breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug QL1706 to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 30 patients with stage II or III disease. Participants receive the combination in two phases over about 8 months, then have surgery. T…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Affiliated Hospital of Nantong University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New peptide drug PQ203 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called PQ203 in about 80 adults with advanced solid tumors, including triple-negative breast cancer, that have not responded to standard treatments. The drug is given as a weekly intravenous infusion. The main goals are to check safety…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for Hard-to-Treat breast cancer: experimental drug MR001 enters human trials
Disease control Recruiting nowThis study tests a new drug called MR001 in people with advanced triple-negative breast cancer (TNBC) whose cancer has worsened after standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 42 participants wil…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug NRM-823 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy aims to boost immune attack on tough breast cancer
Disease control Recruiting nowThis phase 2 trial is testing different ways to combine radiotherapy with the immunotherapy drug toripalimab and chemotherapy for people with advanced triple-negative breast cancer (TNBC). The goal is to find the best schedule that helps control the cancer longer. About 60 partic…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for Hard-to-Treat breast cancer: drug trial targets advanced TNBC
Disease control Recruiting nowThis study tests a new drug called tenalisib in 40 people with metastatic triple negative breast cancer (TNBC) who have already tried 1 to 3 other treatments. The goal is to see if tenalisib can shrink tumors or stop them from growing for at least 16 weeks. Researchers will also …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Rhizen Pharmaceuticals SA • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for aggressive breast cancer: experimental drug ESG401 enters final testing phase
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called ESG401 against standard chemotherapy for people with advanced triple-negative breast cancer that has spread or come back. The study will enroll about 504 participants to see if ESG401 can delay cancer growth and improve survival. It…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New cancer drug NX-1607 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
-
New PET tracers aim to light up Hard-to-See cancers
Diagnosis Recruiting nowThis early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New virtual therapy aims to ease anxiety in TNBC survivors
Symptom relief Recruiting nowThis pilot study tests whether a nurse-led, group-based virtual coping program called RESTORE is feasible and acceptable for people who have finished treatment for triple-negative breast cancer. The program teaches skills like problem-solving, relaxation, and mindfulness to help …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC